|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
affects chemical synthesis |
ISO |
CYP3A4 protein affects the chemical synthesis of 3-hydroxyquinidine |
CTD |
PMID:15896247 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression multiple interactions |
ISO |
Camptothecin results in decreased expression of ABCB1 mRNA; Camptothecin results in decreased expression of ABCB1 protein Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA] |
CTD |
PMID:10692111 PMID:29356861 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases response to substance multiple interactions |
ISO |
ABCC1 protein results in decreased susceptibility to Camptothecin analog Camptothecin inhibits the reaction [ABCC1 results in decreased susceptibility to Daunorubicin] |
CTD |
PMID:11778547 PMID:12115804 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Acvr1b |
activin A receptor type 1B |
increases methylation |
ISO |
Camptothecin results in increased methylation of ACVR1B gene |
CTD |
PMID:30720231 |
|
NCBI chr 7:142,817,174...142,858,365
Ensembl chr 7:142,817,157...142,860,572
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
decreases response to substance |
ISO |
ADAM19 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr10:31,146,107...31,240,582
Ensembl chr10:31,146,107...31,240,582
|
|
G |
Agap1 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 1 |
increases methylation |
ISO |
Camptothecin results in increased methylation of AGAP1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 9:96,718,901...97,034,400
Ensembl chr 9:96,621,586...97,030,163
|
|
G |
Agrn |
agrin |
increases expression |
ISO |
Camptothecin results in increased expression of AGRN mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 5:173,589,910...173,622,813
Ensembl chr 5:173,589,819...173,622,645
|
|
G |
Agrp |
agouti related neuropeptide |
decreases response to substance |
ISO |
AGRP mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr19:37,525,941...37,584,875
Ensembl chr19:37,526,419...37,528,011
|
|
G |
Aifm3 |
apoptosis inducing factor, mitochondria associated 3 |
decreases response to substance |
ISO |
AIFM3 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr11:87,364,452...87,380,705
Ensembl chr11:87,366,621...87,380,704
|
|
G |
Akap13 |
A-kinase anchoring protein 13 |
decreases response to substance |
ISO |
AKAP13 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 1:137,089,558...137,315,272
Ensembl chr 1:137,014,272...137,315,272
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects phosphorylation increases phosphorylation multiple interactions |
ISO |
Camptothecin affects the phosphorylation of AKT1 protein Camptothecin results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Camptothecin results in increased phosphorylation of AKT1 protein]; Nicotine affects the reaction [Camptothecin affects the phosphorylation of AKT1 protein]; Wortmannin inhibits the reaction [Camptothecin results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:24095863 PMID:30851366 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Alb |
albumin |
affects binding multiple interactions |
ISO |
Camptothecin analog binds to ALB protein; Camptothecin binds to ALB protein CTSB protein results in increased cleavage of [Camptothecin analog binds to ALB protein] |
CTD |
PMID:10803926 PMID:17378599 |
|
NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
|
|
G |
Alms1 |
ALMS1, centrosome and basal body associated protein |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of ALMS1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 4:117,371,544...117,472,310
Ensembl chr 4:117,371,659...117,472,198
|
|
G |
Anxa4 |
annexin A4 |
increases expression |
ISO |
Camptothecin results in increased expression of ANXA4 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 4:118,538,775...118,595,591
Ensembl chr 4:118,538,777...118,595,580
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
increases methylation |
ISO |
Camptothecin results in increased methylation of APC gene |
CTD |
PMID:30720231 |
|
NCBI chr18:27,011,710...27,106,323
Ensembl chr18:27,047,382...27,105,531
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:67,656,253...67,828,998
Ensembl chr X:67,656,253...67,829,026
|
|
G |
Artn |
artemin |
decreases response to substance |
ISO |
ARTN mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 5:136,759,717...136,765,036
Ensembl chr 5:136,759,717...136,762,986
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression |
ISO |
Glutathione inhibits the reaction [Camptothecin results in increased expression of ATF4 protein]; MYC protein affects the reaction [Camptothecin results in increased expression of ATF4 protein] |
CTD |
PMID:30266318 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
ATG5 mutant form inhibits the reaction [Camptothecin results in increased degradation of SQSTM1 protein] |
CTD |
PMID:22927544 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions increases expression |
ISO |
Egtazic Acid inhibits the reaction [Camptothecin results in increased expression of ATG7 protein]; EIF2S1 protein affects the reaction [Camptothecin results in increased expression of ATG7 protein]; staurosporine aglycone inhibits the reaction [Camptothecin results in increased expression of ATG7 protein] |
CTD |
PMID:30266318 |
|
NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
|
|
G |
Atm |
ATM serine/threonine kinase |
decreases expression increases expression multiple interactions |
ISO |
Camptothecin results in decreased expression of ATM mRNA Camptothecin results in increased expression of ATM protein modified form Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of ATM protein modified form]; ESR1 promotes the reaction [Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of ATM protein modified form]] |
CTD |
PMID:24792648 PMID:30720231 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atr |
ATR serine/threonine kinase |
decreases response to substance increases phosphorylation multiple interactions |
ISO |
ATR mRNA results in decreased susceptibility to Camptothecin; ATR protein results in decreased susceptibility to Camptothecin Camptothecin results in increased phosphorylation of ATR protein 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide inhibits the reaction [Camptothecin results in increased phosphorylation of ATR protein] |
CTD |
PMID:25269479 PMID:30555576 |
|
NCBI chr 8:103,673,578...103,770,886
Ensembl chr 8:103,673,411...103,770,947
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions decreases expression |
ISO |
Folic Acid inhibits the reaction [Camptothecin results in decreased expression of BAK1 mRNA] |
CTD |
PMID:30581319 |
|
NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions decreases expression increases expression increases activity |
ISO EXP |
[Camptothecin co-treated with 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole] results in decreased expression of BAX protein; Camptothecin affects the cleavage of and results in decreased expression of BAX protein; Folic Acid inhibits the reaction [Camptothecin results in decreased expression of BAX mRNA] Camptothecin results in decreased expression of BAX mRNA; Camptothecin results in decreased expression of BAX protein pifithrin inhibits the reaction [Camptothecin results in increased expression of BAX protein] Camptothecin results in increased activity of BAX protein |
CTD |
PMID:11279278 PMID:15665116 PMID:17555331 PMID:19481069 PMID:30581319 PMID:30885713 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
affects response to substance |
ISO |
BBC3 protein affects the susceptibility to Camptothecin |
CTD |
PMID:20477944 |
|
NCBI chr 1:78,261,491...78,267,802
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression decreases expression decreases response to substance |
ISO |
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in decreased expression of BCL2 protein]; Folic Acid inhibits the reaction [Camptothecin results in decreased expression of BCL2 mRNA] Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein] Camptothecin results in increased expression of BCL2 mRNA Camptothecin results in decreased expression of BCL2 mRNA; Camptothecin results in decreased expression of BCL2 protein BCL2 results in decreased susceptibility to Camptothecin |
CTD |
PMID:9664115 PMID:10692111 PMID:10896673 PMID:19481069 PMID:24726431 PMID:25449198 PMID:30581319 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases response to substance decreases expression multiple interactions increases expression |
EXP ISO |
BCL2L1 gene mutant form results in decreased susceptibility to Camptothecin Camptothecin results in decreased expression of BCL2L1 mRNA Folic Acid inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 mRNA] BCL2L1 mRNA results in decreased susceptibility to Camptothecin Dexamethasone inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 protein alternative form]; Mifepristone affects the reaction [Dexamethasone inhibits the reaction [Camptothecin results in decreased expression of BCL2L1 protein alternative form]]; Naphthoquinones analog promotes the reaction [Camptothecin results in increased expression of BCL2L1 protein] |
CTD |
PMID:10970895 PMID:19339209 PMID:19497415 PMID:25269479 PMID:30581319 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
ISO |
Egtazic Acid inhibits the reaction [Camptothecin results in increased expression of BECN1 protein]; EIF2S1 protein affects the reaction [Camptothecin results in increased expression of BECN1 protein]; staurosporine aglycone inhibits the reaction [Camptothecin results in increased expression of BECN1 protein] |
CTD |
PMID:30266318 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Camptothecin co-treated with 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole] results in increased cleavage of and results in decreased expression of BID protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of BID protein; Camptothecin results in increased cleavage of and results in decreased expression of BID protein |
CTD |
PMID:19481069 PMID:19633536 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression increases expression |
ISO |
[Butyrates co-treated with Camptothecin] results in decreased expression of BIRC5 protein; [Folic Acid co-treated with Camptothecin] results in decreased expression of BIRC5 mRNA Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein] Camptothecin results in decreased expression of BIRC5 mRNA Camptothecin results in increased expression of BIRC5 mRNA |
CTD |
PMID:16061681 PMID:24726431 PMID:25449198 PMID:30581319 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
decreases expression decreases response to substance |
ISO |
Camptothecin results in decreased expression of BRCA1 mRNA BRCA1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:10344722 PMID:25269479 |
|
NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
decreases expression |
ISO |
Camptothecin results in decreased expression of BRCA2 mRNA |
CTD |
PMID:10344722 |
|
NCBI chr12:503,660...544,754
Ensembl chr12:504,007...544,748
|
|
G |
Bscl2 |
BSCL2 lipid droplet biogenesis associated, seipin |
increases expression |
ISO |
Camptothecin results in increased expression of BSCL2 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 1:225,035,956...225,046,137
Ensembl chr 1:225,037,737...225,046,040
|
|
G |
Cab39 |
calcium binding protein 39 |
decreases expression |
ISO |
Camptothecin results in decreased expression of CAB39 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:92,834,327...92,895,778
Ensembl chr 9:92,834,357...92,895,778
|
|
G |
Casp2 |
caspase 2 |
increases splicing increases expression |
ISO |
Camptothecin results in increased splicing of CASP2 mRNA Camptothecin results in increased expression of CASP2 mRNA alternative form |
CTD |
PMID:14757846 |
|
NCBI chr 4:71,652,358...71,670,228
Ensembl chr 4:71,652,354...71,670,239
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity |
ISO EXP |
15-deoxyprostaglandin J2 promotes the reaction [Camptothecin results in increased activity of CASP3 protein]; 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in increased activity of CASP3 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [Camptothecin results in increased activity of CASP3 protein]; [Camptothecin co-treated with FAS protein] results in increased activity of CASP3 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP3 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Camptothecin results in increased cleavage of CASP3 protein]; Camptothecin promotes the reaction [15-deoxyprostaglandin J2 results in increased activity of CASP3 protein]; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased cleavage of CASP3 protein]; palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; SMN1 mRNA affects the reaction [Camptothecin results in increased activity of CASP3 protein]; THBS1 protein inhibits the reaction [Camptothecin results in increased activity of CASP3 protein] Cadmium Chloride inhibits the reaction [Camptothecin results in increased cleavage of CASP3 protein]; Cadmium inhibits the reaction [Camptothecin results in increased cleavage of CASP3 protein]; Dexamethasone inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; Naphthoquinones analog inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; Tetrachlorodibenzodioxin promotes the reaction [Camptothecin results in increased cleavage of CASP3 protein] |
CTD |
PMID:10896673 PMID:15862279 PMID:15958570 PMID:16263807 PMID:16273314 PMID:16756956 PMID:16962673 PMID:18506790 PMID:19339209 PMID:19481069 PMID:19497415 PMID:19633536 PMID:21683069 PMID:22302033 PMID:24726431 PMID:24792648 PMID:25412314 PMID:25592883 PMID:25843524 PMID:29384525 PMID:30720231 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
multiple interactions decreases expression increases activity |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Camptothecin results in increased activity of CASP7 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [Camptothecin results in increased activity of CASP7 protein]; palbociclib inhibits the reaction [Camptothecin results in increased activity of CASP7 protein] Camptothecin results in decreased expression of CASP7 mRNA |
CTD |
PMID:22302033 PMID:24726431 PMID:30581319 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
multiple interactions decreases expression increases expression increases activity affects cleavage |
ISO EXP |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Camptothecin results in increased activity of CASP8 protein]; [Camptothecin co-treated with FAS protein] results in increased activity of CASP8 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP8 protein; Lithium inhibits the reaction [Camptothecin results in increased activity of CASP8 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CASP8 protein] Camptothecin results in decreased expression of CASP8 mRNA Naphthoquinones analog inhibits the reaction [Camptothecin results in increased activity of CASP8 protein] Camptothecin affects the cleavage of CASP8 protein |
CTD |
PMID:10896673 PMID:15475000 PMID:15958570 PMID:19497415 PMID:19633536 PMID:30581319 PMID:30885713 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions decreases expression increases expression increases cleavage increases activity |
ISO EXP |
[Camptothecin co-treated with FAS protein] results in increased activity of CASP9 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP9 protein; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CASP9 protein] Camptothecin results in decreased expression of CASP9 mRNA Camptothecin results in increased cleavage of CASP9 protein Camptothecin results in increased activity of CASP9 protein benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Camptothecin results in increased cleavage of CASP9 protein]; Cadmium Chloride inhibits the reaction [Camptothecin results in increased activity of CASP9 protein]; Cadmium inhibits the reaction [Camptothecin results in increased activity of CASP9 protein]; Naphthoquinones analog inhibits the reaction [Camptothecin results in increased activity of CASP9 protein] |
CTD |
PMID:10896673 PMID:15958570 PMID:16263807 PMID:19497415 PMID:19633536 PMID:24823293 PMID:30581319 PMID:30885713 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cav1 |
caveolin 1 |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of CAV1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Camptothecin results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Camptothecin results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
Camptothecin results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[Folic Acid co-treated with Camptothecin] results in decreased expression of CCNA2 mRNA Camptothecin results in decreased expression of CCNA2 mRNA |
CTD |
PMID:30581319 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions decreases expression increases expression |
ISO |
[Butyrates co-treated with Camptothecin] results in decreased expression of CCNB1 protein; CDKN1A protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein] Camptothecin results in decreased expression of CCNB1 protein |
CTD |
PMID:16061681 PMID:23376119 PMID:30851366 PMID:30885713 PMID:31255635 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnd1 |
cyclin D1 |
affects localization |
ISO |
Camptothecin affects the localization of CCND1 protein |
CTD |
PMID:14647467 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO |
Camptothecin results in increased expression of CCNE1 protein |
CTD |
PMID:30851366 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
Camptothecin promotes the reaction [MAD2L1 protein binds to CDC20 protein] |
CTD |
PMID:30885713 |
|
NCBI chr 5:137,260,728...137,264,931
Ensembl chr 5:137,260,739...137,265,015
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
Camptothecin results in increased expression of and results in increased activity of CDK1 protein; CDKN1A protein affects the reaction [Camptothecin results in increased activity of CDK1 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of and results in increased activity of CDK1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of CDK1 protein] |
CTD |
PMID:30885713 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
Camptothecin results in increased phosphorylation of and results in decreased activity of CDK2 protein |
CTD |
PMID:15141020 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
Aspirin inhibits the reaction [Camptothecin results in increased expression of CDKN1A protein]; Camptothecin results in increased expression of and results in increased phosphorylation of CDKN1A protein; CDKN1A protein affects the reaction [Camptothecin results in increased activity of CDK1 protein]; CDKN1A protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; CDKN1A protein affects the reaction [Camptothecin results in increased expression of MAD2L1 protein] Camptothecin results in increased expression of CDKN1A mRNA; Camptothecin results in increased expression of CDKN1A protein |
CTD |
PMID:9673414 PMID:17555331 PMID:19212664 PMID:24211769 PMID:30022047 PMID:30851366 PMID:30885713 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
ISO |
Camptothecin results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:82,327,955...82,344,345
Ensembl chr 1:82,327,955...82,344,345
|
|
G |
Cebpz |
CCAAT/enhancer binding protein zeta |
decreases expression |
ISO |
Camptothecin results in decreased expression of CEBPZ mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:1,516,804...1,534,488
Ensembl chr 6:1,516,804...1,534,488
|
|
G |
Cep85l |
centrosomal protein 85-like |
increases methylation |
ISO |
Camptothecin results in increased methylation of CEP85L gene |
CTD |
PMID:30720231 |
|
NCBI chr20:34,574,043...34,743,142
Ensembl chr20:34,575,950...34,684,418
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein] |
CTD |
PMID:25449198 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions increases phosphorylation decreases response to substance increases expression |
ISO |
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Camptothecin results in increased phosphorylation of CHEK1 protein]; 7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of CHEK1 mRNA]; 7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased phosphorylation of CHEK1 protein]; Caffeine inhibits the reaction [Camptothecin results in increased expression of CHEK1 mRNA]; Caffeine inhibits the reaction [Camptothecin results in increased phosphorylation of CHEK1 protein] CHEK1 mRNA results in decreased susceptibility to Camptothecin Camptothecin results in increased expression of CHEK1 protein modified form 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide inhibits the reaction [Camptothecin results in increased expression of CHEK1 protein modified form]; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of CHEK1 protein modified form] |
CTD |
PMID:21646468 PMID:22403396 PMID:25269479 PMID:30555576 PMID:30720231 |
|
NCBI chr 8:39,181,162...39,201,588
Ensembl chr 8:39,181,163...39,243,882
|
|
G |
Chek2 |
checkpoint kinase 2 |
increases expression multiple interactions increases phosphorylation |
ISO |
Camptothecin results in increased expression of CHEK2 protein modified form Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of CHEK2 protein modified form] Camptothecin results in increased phosphorylation of CHEK2 protein |
CTD |
PMID:21646468 PMID:25269479 PMID:25977998 PMID:30720231 |
|
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
|
|
G |
Clptm1l |
CLPTM1-like |
increases response to substance |
ISO |
CLPTM1L mutant form results in increased susceptibility to Camptothecin |
CTD |
PMID:22675468 |
|
NCBI chr 1:32,281,207...32,297,196
Ensembl chr 1:32,281,207...32,297,190
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
EXP |
Camptothecin inhibits the reaction [RELA protein binds to CREBBP protein]; Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]; pifithrin inhibits the reaction [Camptothecin inhibits the reaction [RELA protein binds to CREBBP protein]]; pifithrin inhibits the reaction [Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]] |
CTD |
PMID:13679428 |
|
NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
|
|
G |
Crx |
cone-rod homeobox |
decreases response to substance |
ISO |
CRX mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 1:77,744,593...77,758,913
Ensembl chr 1:77,745,288...77,750,960
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
CTSB protein results in increased cleavage of [Camptothecin analog binds to ALB protein] |
CTD |
PMID:17378599 |
|
NCBI chr15:46,316,741...46,337,613
Ensembl chr15:46,316,741...46,337,612
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions affects localization |
ISO |
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin affects the localization of CYCS protein] |
CTD |
PMID:19481069 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
decreases response to substance |
ISO |
CYP26B1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 4:116,261,796...116,278,615
Ensembl chr 4:116,261,796...116,278,615
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases expression multiple interactions |
ISO |
Camptothecin results in decreased expression of CYP2B6 mRNA Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA] |
CTD |
PMID:29356861 |
|
NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases expression multiple interactions |
ISO |
Camptothecin results in decreased expression of CYP2C8 mRNA Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA] |
CTD |
PMID:29356861 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA] |
CTD |
PMID:29356861 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions decreases expression increases expression |
ISO |
Folic Acid inhibits the reaction [Camptothecin results in decreased expression of DDIT3 mRNA]; MYC protein affects the reaction [Camptothecin results in increased expression of DDIT3 protein] |
CTD |
PMID:30266318 PMID:30581319 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dgkz |
diacylglycerol kinase zeta |
decreases response to substance |
ISO |
DGKZ mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 3:80,844,002...80,886,487
Ensembl chr 3:80,844,005...80,875,817
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
multiple interactions decreases activity decreases expression |
ISO |
Camptothecin inhibits the reaction [Fluorouracil results in increased expression of DPYD mRNA] Camptothecin results in decreased activity of DPYD protein Camptothecin results in decreased expression of DPYD mRNA |
CTD |
PMID:16568373 |
|
NCBI chr 2:221,823,692...222,694,627
Ensembl chr 2:221,823,687...222,694,627
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions increases expression |
ISO |
7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of E2F1 mRNA]; Caffeine inhibits the reaction [Camptothecin results in increased expression of E2F1 mRNA]; E2F1 protein promotes the reaction [Camptothecin results in increased expression of RRM2 protein] |
CTD |
PMID:22403396 |
|
NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
|
|
G |
Ei24 |
EI24, autophagy associated transmembrane protein |
increases expression |
ISO |
Camptothecin results in increased expression of EI24 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 8:39,254,883...39,271,238
Ensembl chr 8:39,254,889...39,266,959
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Glutathione inhibits the reaction [Camptothecin results in increased phosphorylation of EIF2AK3 protein]; MYC protein affects the reaction [Camptothecin results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:30266318 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO EXP |
Camptothecin results in increased phosphorylation of EIF2S1 protein [Camptothecin co-treated with GW 506033X] results in increased phosphorylation of EIF2S1 protein EIF2S1 protein affects the reaction [Camptothecin results in increased expression of ATG7 protein]; EIF2S1 protein affects the reaction [Camptothecin results in increased expression of BECN1 protein]; Glutathione inhibits the reaction [Camptothecin results in increased phosphorylation of EIF2S1 protein]; MYC protein affects the reaction [Camptothecin results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:19046382 PMID:30266318 |
|
NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
|
|
G |
Ep300 |
E1A binding protein p300 |
decreases expression |
ISO |
Camptothecin results in decreased expression of EP300 mRNA; Camptothecin results in decreased expression of EP300 protein |
CTD |
PMID:10344722 |
|
NCBI chr 7:122,818,194...122,889,055
Ensembl chr 7:122,818,975...122,861,296
|
|
G |
Epm2aip1 |
EPM2A interacting protein 1 |
increases expression |
ISO |
Camptothecin results in increased expression of EPM2AIP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 8:119,524,039...119,531,387
Ensembl chr 8:119,524,039...119,531,387
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
multiple interactions decreases expression |
ISO |
ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] Camptothecin results in decreased expression of ERCC1 mRNA |
CTD |
PMID:21227924 PMID:24792648 |
|
NCBI chr 1:80,256,973...80,268,198
Ensembl chr 1:80,256,973...80,268,198
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
multiple interactions decreases response to substance |
ISO |
ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] ERCC4 protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:21227924 |
|
NCBI chr10:2,010,140...2,037,953
Ensembl chr10:2,010,648...2,037,891
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of ESR1 protein; ESR1 promotes the reaction [Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of ATM protein modified form]]; ESR1 promotes the reaction [Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]] |
CTD |
PMID:25752796 PMID:30720231 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of ESR2 protein |
CTD |
PMID:25752796 |
|
NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione inhibits the reaction [Camptothecin results in increased expression of and affects the localization of FAS protein]; [Camptothecin co-treated with FAS protein] results in decreased expression of XIAP protein; [Camptothecin co-treated with FAS protein] results in increased activity of CASP3 protein; [Camptothecin co-treated with FAS protein] results in increased activity of CASP8 protein; [Camptothecin co-treated with FAS protein] results in increased activity of CASP9 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of BID protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP3 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP8 protein; [Camptothecin co-treated with FAS protein] results in increased cleavage of CASP9 protein; Camptothecin results in increased expression of and affects the localization of FAS protein; Lithium inhibits the reaction [Camptothecin results in increased expression of and affects the localization of FAS protein] |
CTD |
PMID:15475000 PMID:15958570 PMID:19633536 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fdxr |
ferredoxin reductase |
increases expression |
ISO |
Camptothecin results in increased expression of FDXR mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:103,817,724...103,826,413
Ensembl chr10:103,817,704...103,826,448
|
|
G |
Fxn |
frataxin |
increases expression |
ISO |
Camptothecin results in increased expression of FXN protein |
CTD |
PMID:23418481 |
|
NCBI chr 1:242,123,975...242,152,834
Ensembl chr 1:242,123,975...242,152,834
|
|
G |
Fzd1 |
frizzled class receptor 1 |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of FZD1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 4:26,470,864...26,475,262
Ensembl chr 4:26,470,864...26,475,262
|
|
G |
Fzd8 |
frizzled class receptor 8 |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of FZD8 gene |
CTD |
PMID:30720231 |
|
NCBI chr17:62,259,910...62,267,239
Ensembl chr17:62,262,129...62,265,113
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
decreases expression multiple interactions |
ISO |
Camptothecin results in decreased expression of GADD45A mRNA Folic Acid inhibits the reaction [Camptothecin results in decreased expression of GADD45A mRNA] |
CTD |
PMID:24792648 PMID:30581319 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gadd45g |
growth arrest and DNA-damage-inducible, gamma |
increases expression |
ISO |
Camptothecin results in increased expression of GADD45G mRNA |
CTD |
PMID:24792648 |
|
NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243
|
|
G |
Git2 |
GIT ArfGAP 2 |
decreases response to substance |
ISO |
GIT2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr12:47,590,110...47,630,991
Ensembl chr12:47,590,154...47,631,119
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
decreases response to substance |
ISO |
GPX4 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
increases expression decreases response to substance |
ISO |
Camptothecin results in increased expression of GSTP1 protein GSTP1 protein polymorphism results in decreased susceptibility to Camptothecin; GSTP1 protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:14732228 PMID:15500952 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions increases expression increases phosphorylation |
ISO EXP |
3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; [Aminacrine results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; [MIR138-1 results in decreased expression of H2AX] which results in increased susceptibility to Camptothecin; [Propyl Gallate results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; ERCC1 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ERCC4 protein promotes the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; ESR1 promotes the reaction [Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]]; H2AX gene mutant form inhibits the reaction [MIR138-1 results in increased susceptibility to Camptothecin]; palbociclib inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; PPP2R2A protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; PPP2R5C protein promotes the reaction [Camptothecin results in increased expression of H2AX protein modified form]; PPP2R5E protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form]; TDP1 protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]]; veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein] Camptothecin results in increased phosphorylation of H2AX protein Camptothecin results in increased expression of H2AX protein; Camptothecin results in increased expression of H2AX protein modified form |
CTD |
PMID:17875725 PMID:21227924 PMID:21646468 PMID:21693595 PMID:22302033 PMID:25269479 PMID:25772433 PMID:26928355 PMID:30720231 PMID:32482060 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
decreases expression |
ISO |
Camptothecin results in decreased expression of HAMP mRNA |
CTD |
PMID:25633564 |
|
NCBI chr 1:89,368,021...89,369,960
Ensembl chr 1:89,368,021...89,369,960
|
|
G |
Hemk1 |
HemK methyltransferase family member 1 |
decreases response to substance |
ISO |
HEMK1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 8:116,081,858...116,092,872
Ensembl chr 8:116,082,005...116,092,763
|
|
G |
Hnrnpc |
heterogeneous nuclear ribonucleoprotein C |
multiple interactions |
ISO |
[HNRNPC protein binds to HNRNPC protein alternative form] which results in decreased susceptibility to Camptothecin |
CTD |
PMID:16960656 |
|
NCBI chr15:28,486,605...28,517,353
Ensembl chr15:28,486,617...28,517,353
|
|
G |
Hoxa1 |
homeobox A1 |
decreases response to substance multiple interactions |
ISO |
HOXA1 mRNA results in decreased susceptibility to Camptothecin Camptothecin inhibits the reaction [Vitamin A results in increased expression of HOXA1] |
CTD |
PMID:25269479 PMID:26820057 |
|
NCBI chr 4:82,124,358...82,127,182
Ensembl chr 4:82,125,406...82,127,066
|
|
G |
Ibsp |
integrin-binding sialoprotein |
decreases response to substance |
ISO |
IBSP mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr14:6,801,200...6,813,987
Ensembl chr14:6,801,204...6,813,945
|
|
G |
Il1b |
interleukin 1 beta |
decreases response to substance |
ISO |
IL1B protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:16356833 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Camptothecin results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:189,196,180...189,255,987
Ensembl chr 2:189,205,701...189,254,628
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions increases phosphorylation |
ISO EXP |
Camptothecin results in increased expression of JUN protein Glutathione inhibits the reaction [Camptothecin results in increased phosphorylation of JUN protein]; MAPK8 protein affects the reaction [Camptothecin results in increased phosphorylation of JUN protein] |
CTD |
PMID:9751194 PMID:15585644 PMID:30266318 PMID:30885713 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Kcnk2 |
potassium two pore domain channel subfamily K member 2 |
decreases response to substance |
ISO |
KCNK2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr13:107,690,111...107,886,476
Ensembl chr13:107,690,087...107,886,476
|
|
G |
Lgals1 |
galectin 1 |
decreases expression |
ISO |
Camptothecin results in decreased expression of LGALS1 mRNA; Camptothecin results in decreased expression of LGALS1 protein |
CTD |
PMID:19483324 |
|
NCBI chr 7:120,153,184...120,156,290
Ensembl chr 7:120,153,184...120,156,289
|
|
G |
Lrch4 |
leucine rich repeats and calponin homology domain containing 4 |
decreases response to substance |
ISO |
LRCH4 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr12:22,127,387...22,138,436
Ensembl chr12:22,127,393...22,138,382
|
|
G |
Mad2l1 |
mitotic arrest deficient 2 like 1 |
multiple interactions increases expression |
ISO |
Camptothecin promotes the reaction [MAD2L1 protein binds to CDC20 protein]; CDKN1A protein affects the reaction [Camptothecin results in increased expression of MAD2L1 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of and results in increased activity of CDK1 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CASP8 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CASP9 protein]; MAD2L1 protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of MAD2L1 protein] Camptothecin results in increased expression of MAD2L1 mRNA; Camptothecin results in increased expression of MAD2L1 protein |
CTD |
PMID:30885713 |
|
NCBI chr 4:97,530,993...97,543,179
Ensembl chr 4:97,531,083...97,537,086
|
|
G |
Map2k3 |
mitogen activated protein kinase kinase 3 |
increases expression |
ISO |
Camptothecin results in increased expression of MAP2K3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:45,089,455...45,110,802
Ensembl chr10:47,182,433...47,203,753
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
decreases expression |
ISO |
Camptothecin results in decreased expression of MAP3K5 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:15,412,603...15,613,752
Ensembl chr 1:15,412,603...15,613,746
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
decreases response to substance |
ISO |
MAP3K7 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 5:47,183,142...47,244,424
Ensembl chr 5:47,186,558...47,244,416
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Camptothecin co-treated with Nicotine] results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:24095863 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Camptothecin co-treated with Nicotine] results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:24095863 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation multiple interactions |
ISO |
Camptothecin results in increased phosphorylation of MAPK8 protein MAPK8 protein affects the reaction [Camptothecin results in increased activity of SP1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of CCNB1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of CDK1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased expression of MAD2L1 protein]; MAPK8 protein affects the reaction [Camptothecin results in increased phosphorylation of JUN protein] |
CTD |
PMID:30885713 PMID:31255635 |
|
NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases phosphorylation |
ISO |
Camptothecin results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:15585644 |
|
NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
Camptothecin results in decreased expression of MAPT mRNA; Camptothecin results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Mdc1 |
mediator of DNA damage checkpoint 1 |
multiple interactions |
ISO |
[Aminacrine results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; [Propyl Gallate results in decreased phosphorylation of H2AX protein] inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; Aminacrine inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein]; Camptothecin results in increased activity of and affects the localization of MDC1 protein; Propyl Gallate inhibits the reaction [Camptothecin results in increased activity of and affects the localization of MDC1 protein] |
CTD |
PMID:26928355 |
|
NCBI chr20:3,405,017...3,419,831
Ensembl chr20:3,404,711...3,419,831
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
Camptothecin results in increased expression of MDM2 protein |
CTD |
PMID:17555331 |
|
NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases expression |
ISO |
Camptothecin results in decreased expression of MGMT mRNA |
CTD |
PMID:18492797 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Mir138-1 |
microRNA 138-1 |
multiple interactions increases response to substance |
ISO |
[MIR138-1 results in decreased expression of H2AX] which results in increased susceptibility to Camptothecin; H2AX gene mutant form inhibits the reaction [MIR138-1 results in increased susceptibility to Camptothecin] |
CTD |
PMID:21693595 |
|
NCBI chr 8:131,731,726...131,731,824
Ensembl chr 8:131,731,726...131,731,824
|
|
G |
Mir145 |
microRNA 145 |
increases expression decreases expression |
ISO |
Camptothecin results in increased expression of MIR145 mRNA Camptothecin results in decreased expression of MIR145 mRNA |
CTD |
PMID:24726431 |
|
NCBI chr18:56,969,907...56,969,994
Ensembl chr18:56,969,907...56,969,994
|
|
G |
Mir34a |
microRNA 34a |
increases expression |
ISO |
Camptothecin results in increased expression of MIR34A mRNA |
CTD |
PMID:24726431 |
|
NCBI chr 5:167,092,491...167,092,592
Ensembl chr 5:167,092,491...167,092,592
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases response to substance decreases methylation |
ISO |
MMP9 mRNA results in decreased susceptibility to Camptothecin Camptothecin results in decreased methylation of MMP9 gene |
CTD |
PMID:25269479 PMID:30720231 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
decreases expression |
ISO |
Camptothecin results in decreased expression of MRE11 mRNA |
CTD |
PMID:24792648 |
|
NCBI chr 8:13,304,355...13,350,329
Ensembl chr 8:13,305,152...13,352,489
|
|
G |
Mtmr2 |
myotubularin related protein 2 |
decreases response to substance |
ISO |
MTMR2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 8:12,283,471...12,334,014
Ensembl chr 8:12,284,528...12,333,316
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases expression |
ISO |
Camptothecin results in decreased expression of MTOR protein |
CTD |
PMID:31255635 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression multiple interactions affects localization |
ISO |
Camptothecin results in increased expression of MYC mRNA Camptothecin results in increased expression of and results in increased activity of MYC protein; MYC protein affects the reaction [Camptothecin results in increased expression of ATF4 protein]; MYC protein affects the reaction [Camptothecin results in increased expression of DDIT3 protein]; MYC protein affects the reaction [Camptothecin results in increased phosphorylation of EIF2AK3 protein]; MYC protein affects the reaction [Camptothecin results in increased phosphorylation of EIF2S1 protein]; TERT protein affects the reaction [Camptothecin results in increased expression of MYC protein] Camptothecin affects the localization of MYC protein |
CTD |
PMID:30266318 PMID:30851366 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
decreases response to substance |
ISO |
NCAM1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 8:53,836,797...54,134,881
Ensembl chr 8:53,839,098...53,901,358
|
|
G |
Nck2 |
NCK adaptor protein 2 |
decreases expression |
ISO |
Camptothecin results in decreased expression of NCK2 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:50,246,767...50,373,307
Ensembl chr 9:50,247,692...50,373,284
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]] |
CTD |
PMID:29356861 |
|
NCBI chr 6:28,677,563...28,931,844
Ensembl chr 6:28,677,540...28,931,843
|
|
G |
Ncor2 |
nuclear receptor co-repressor 2 |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [NCOR2 protein binds to NR1I2 protein] |
CTD |
PMID:29356861 |
|
NCBI chr12:36,871,917...37,033,701
Ensembl chr12:36,871,999...37,033,701
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions increases activity |
ISO |
NFE2L2 protein affects the reaction [Camptothecin results in increased expression of TERT mRNA] Camptothecin results in increased activity of NFE2L2 protein |
CTD |
PMID:30851366 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
Camptothecin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Camptothecin inhibits the reaction [Rifampin results in increased activity of NR1I2 protein] |
CTD |
PMID:29356861 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Olr1086 |
olfactory receptor 1086 |
decreases response to substance |
ISO |
OR7C2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 7:13,698,647...13,699,609
Ensembl chr 7:13,698,647...13,699,609
|
|
G |
Olr1514 |
olfactory receptor 1514 |
decreases response to substance |
ISO |
OR1A2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr10:61,044,411...61,045,355
Ensembl chr10:61,044,411...61,045,355
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions affects response to substance decreases response to substance increases cleavage |
ISO EXP |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [Camptothecin results in increased cleavage of PARP1 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; Camptothecin results in increased ADP-ribosylation of and results in increased degradation of PARP1 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Camptothecin results in increased ADP-ribosylation of and results in increased degradation of PARP1 protein]; Nicotine inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; PARP1 protein promotes the reaction [Camptothecin results in increased abundance of Poly Adenosine Diphosphate Ribose]; RBL2 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein]; THBS1 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein] PARP1 protein affects the susceptibility to Camptothecin PARP1 results in decreased susceptibility to Camptothecin Tetrachlorodibenzodioxin promotes the reaction [Camptothecin results in increased cleavage of PARP1 protein] [Camptothecin co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased cleavage of PARP1 protein; [veliparib results in decreased activity of PARP1 protein] which results in increased susceptibility to Camptothecin |
CTD |
PMID:11741290 PMID:15585644 PMID:16962673 PMID:18506790 PMID:19559722 PMID:22158865 PMID:23376119 PMID:24095863 PMID:24726431 PMID:24792648 PMID:24823293 PMID:25412314 PMID:25449198 PMID:25843524 PMID:27694308 PMID:29384525 PMID:31255635 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:7,128,656...7,187,796
Ensembl chr 8:7,128,656...7,187,796
|
|
G |
Plk3 |
polo-like kinase 3 |
increases expression |
ISO |
Camptothecin results in increased expression of PLK3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 5:135,997,725...136,002,900
Ensembl chr 5:135,997,725...136,002,900
|
|
G |
Ppp1r16b |
protein phosphatase 1, regulatory subunit 16B |
decreases response to substance |
ISO |
PPP1R16B mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 3:155,160,474...155,267,002
Ensembl chr 3:155,160,481...155,262,941
|
|
G |
Ppp1r1b |
protein phosphatase 1, regulatory (inhibitor) subunit 1B |
decreases response to substance |
ISO |
PPP1R1B protein alternative form results in decreased susceptibility to Camptothecin; PPP1R1B protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:16061638 |
|
NCBI chr10:86,303,727...86,312,770
Ensembl chr10:86,303,727...86,312,762
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
multiple interactions |
ISO |
Camptothecin affects the localization of [PPP2R5E protein binds to PPP2CA protein] |
CTD |
PMID:25772433 |
|
NCBI chr10:37,534,449...37,554,861
Ensembl chr10:37,535,871...37,554,664
|
|
G |
Ppp2r1a |
protein phosphatase 2 scaffold subunit A alpha |
affects localization decreases response to substance |
ISO |
Camptothecin affects the localization of PPP2R1A protein PPP2R1A mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 PMID:25772433 |
|
NCBI chr 1:60,717,386...60,736,629
Ensembl chr 1:60,717,386...60,736,609
|
|
G |
Ppp2r2a |
protein phosphatase 2, regulatory subunit B, alpha |
multiple interactions decreases response to substance |
ISO |
PPP2R2A protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form] PPP2R2A protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:25772433 |
|
NCBI chr15:43,673,958...43,733,182
Ensembl chr15:43,673,960...43,733,182
|
|
G |
Ppp2r5c |
protein phosphatase 2, regulatory subunit B', gamma |
multiple interactions increases response to substance |
ISO |
PPP2R5C protein promotes the reaction [Camptothecin results in increased expression of H2AX protein modified form] PPP2R5C protein results in increased susceptibility to Camptothecin |
CTD |
PMID:25772433 |
|
NCBI chr 6:134,804,128...134,941,912
Ensembl chr 6:134,804,141...134,939,358
|
|
G |
Ppp2r5e |
protein phosphatase 2 regulatory subunit B', epsilon |
multiple interactions decreases response to substance |
ISO |
Camptothecin affects the localization of [PPP2R5E protein binds to PPP2CA protein]; PPP2R5E protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein modified form] PPP2R5E protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:25772433 |
|
NCBI chr 6:98,417,974...98,567,016
Ensembl chr 6:98,417,974...98,566,966
|
|
G |
Prc1 |
protein regulator of cytokinesis 1 |
decreases expression |
ISO |
Camptothecin results in decreased expression of PRC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 1:142,087,181...142,108,746
Ensembl chr 1:142,087,208...142,108,746
|
|
G |
Ptar1 |
protein prenyltransferase alpha subunit repeat containing 1 |
decreases response to substance |
ISO |
PTAR1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 1:241,501,679...241,557,651
Ensembl chr 1:241,501,679...241,557,651
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Camptothecin results in decreased expression of and results in decreased phosphorylation of PTEN protein |
CTD |
PMID:30885713 |
|
NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
|
|
G |
Ptpro |
protein tyrosine phosphatase, receptor type, O |
decreases response to substance |
ISO |
PTPRO mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 4:171,250,766...171,461,571
Ensembl chr 4:171,250,818...171,461,677
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
decreases expression |
ISO |
Camptothecin results in decreased expression of RAD50 mRNA |
CTD |
PMID:24792648 |
|
NCBI chr10:39,002,130...39,054,042
Ensembl chr10:39,001,498...39,054,142
|
|
G |
Rad51 |
RAD51 recombinase |
decreases expression |
ISO |
Camptothecin results in decreased expression of RAD51 mRNA; Camptothecin results in decreased expression of RAD51 protein |
CTD |
PMID:10344722 PMID:24792648 |
|
NCBI chr 3:110,918,240...110,942,920
Ensembl chr 3:110,918,243...110,942,917
|
|
G |
Rad51c |
RAD51 paralog C |
increases response to substance |
ISO |
RAD51C gene mutant form results in increased susceptibility to Camptothecin |
CTD |
PMID:20400963 |
|
NCBI chr10:74,697,713...74,724,004
Ensembl chr10:74,697,716...74,724,472
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases methylation |
ISO |
Camptothecin results in increased methylation of RARA gene |
CTD |
PMID:30720231 |
|
NCBI chr10:86,838,819...86,884,224
Ensembl chr10:86,860,685...86,884,210
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases phosphorylation affects response to substance |
ISO |
Camptothecin results in increased phosphorylation of RB1 protein RB1 protein affects the susceptibility to Camptothecin |
CTD |
PMID:14647467 PMID:14704340 PMID:15064736 PMID:15585644 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
decreases expression |
ISO |
Camptothecin results in decreased expression of RBL1 protein |
CTD |
PMID:15585644 |
|
NCBI chr 3:153,263,692...153,321,351
Ensembl chr 3:153,263,692...153,321,352
|
|
G |
Rbl2 |
RB transcriptional corepressor like 2 |
multiple interactions decreases response to substance |
ISO |
RBL2 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein] RBL2 protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:15585644 |
|
NCBI chr19:17,300,088...17,346,865
Ensembl chr19:17,300,089...17,346,808
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases response to substance multiple interactions |
ISO EXP |
RELA results in increased susceptibility to Camptothecin Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein] Camptothecin inhibits the reaction [RELA protein binds to CREBBP protein]; pifithrin inhibits the reaction [Camptothecin inhibits the reaction [RELA protein binds to CREBBP protein]] |
CTD |
PMID:13679428 PMID:21737676 PMID:25449198 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Ret |
ret proto-oncogene |
decreases expression |
EXP |
Camptothecin results in decreased expression of RET protein |
CTD |
PMID:17555550 |
|
NCBI chr 4:150,202,170...150,249,196
Ensembl chr 4:150,202,058...150,244,372
|
|
G |
Rnf31 |
ring finger protein 31 |
decreases response to substance |
ISO |
RNF31 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr15:34,270,037...34,282,385
Ensembl chr15:34,270,648...34,282,495
|
|
G |
Rps6 |
ribosomal protein S6 |
increases expression |
ISO |
Camptothecin results in increased expression of RPS6 protein modified form |
CTD |
PMID:29384525 |
|
NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
multiple interactions increases expression |
ISO |
2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one inhibits the reaction [Camptothecin results in increased expression of RRM2 protein]; 7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of RRM2 mRNA]; 7-hydroxystaurosporine inhibits the reaction [Camptothecin results in increased expression of RRM2 protein]; Caffeine inhibits the reaction [Camptothecin results in increased expression of RRM2 mRNA]; Caffeine inhibits the reaction [Camptothecin results in increased expression of RRM2 protein]; E2F1 protein promotes the reaction [Camptothecin results in increased expression of RRM2 protein] Camptothecin results in increased expression of RRM2 mRNA; Camptothecin results in increased expression of RRM2 protein |
CTD |
PMID:22403396 |
|
NCBI chr 6:43,884,627...43,890,818
Ensembl chr 6:43,884,678...43,889,515
|
|
G |
Sdc1 |
syndecan 1 |
increases expression |
ISO |
Camptothecin results in increased expression of SDC1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 6:33,885,576...33,908,038
Ensembl chr 6:33,885,495...33,908,016
|
|
G |
Sel1l |
SEL1L adaptor subunit of ERAD E3 ubiquitin ligase |
decreases response to substance |
ISO |
SEL1L mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 6:115,572,683...115,616,904
Ensembl chr 6:115,572,649...115,616,859
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions decreases expression |
ISO |
[SIRT1 mutant form co-treated with Camptothecin] results in increased acetylation of TP53 protein; Camptothecin inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in increased expression of SIRT1 protein] Camptothecin results in decreased expression of SIRT1 protein |
CTD |
PMID:24726431 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Slc2a12 |
solute carrier family 2 member 12 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SLC2A12 gene |
CTD |
PMID:30720231 |
|
NCBI chr 1:24,003,625...24,056,373
Ensembl chr 1:24,003,625...24,056,373
|
|
G |
Smn1 |
survival of motor neuron 1, telomeric |
multiple interactions increases response to substance |
ISO |
SMN1 mRNA affects the reaction [Camptothecin results in increased activity of CASP3 protein] SMN1 protein results in increased susceptibility to Camptothecin |
CTD |
PMID:15862279 |
|
NCBI chr 2:30,360,101...30,371,147
Ensembl chr 2:30,360,100...30,371,147
|
|
G |
Smpd3 |
sphingomyelin phosphodiesterase 3 |
increases expression |
ISO |
Camptothecin results in increased expression of SMPD3 mRNA |
CTD |
PMID:19698806 |
|
NCBI chr19:38,237,963...38,321,572
Ensembl chr19:38,237,965...38,321,528
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression multiple interactions |
ISO |
Camptothecin results in increased expression of SOD1 protein Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of SOD1 protein] |
CTD |
PMID:30720231 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
Diethylhexyl Phthalate inhibits the reaction [Camptothecin results in increased expression of SOD2 protein] |
CTD |
PMID:30720231 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sox11 |
SRY-box transcription factor 11 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX11 gene |
CTD |
PMID:30720231 |
|
NCBI chr 6:46,629,967...46,631,988
Ensembl chr 6:46,629,974...46,631,983
|
|
G |
Sox12 |
SRY-box transcription factor 12 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX12 gene |
CTD |
PMID:30720231 |
|
NCBI chr 3:147,864,374...147,865,393
Ensembl chr 3:147,864,374...147,865,393
|
|
G |
Sox17 |
SRY-box transcription factor 17 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX17 gene |
CTD |
PMID:30720231 |
|
NCBI chr 5:14,890,318...14,895,907
Ensembl chr 5:14,890,408...14,895,907
|
|
G |
Sox3 |
SRY-box transcription factor 3 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX3 gene |
CTD |
PMID:30720231 |
|
NCBI chr X:144,035,162...144,037,364
Ensembl chr X:144,035,883...144,037,294
|
|
G |
Sox4 |
SRY-box transcription factor 4 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX4 gene |
CTD |
PMID:30720231 |
|
NCBI chr17:37,615,022...37,619,728
|
|
G |
Sox8 |
SRY-box transcription factor 8 |
increases methylation |
ISO |
Camptothecin results in increased methylation of SOX8 gene |
CTD |
PMID:30720231 |
|
NCBI chr10:14,932,348...14,937,336
Ensembl chr10:14,932,348...14,937,336
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions increases expression increases activity |
ISO |
Acetylcysteine inhibits the reaction [Camptothecin results in increased expression of SP1 mRNA]; Camptothecin results in increased activity of and affects the localization of SP1 protein; Camptothecin results in increased expression of and results in increased activity of SP1 protein; MAPK8 protein affects the reaction [Camptothecin results in increased activity of SP1 protein]; mithramycin A inhibits the reaction [Camptothecin results in increased activity of SP1 protein]; TERT protein affects the reaction [Camptothecin results in increased expression of SP1 protein] |
CTD |
PMID:11261509 PMID:30851366 PMID:30885713 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Sp3 |
Sp3 transcription factor |
increases activity multiple interactions |
ISO |
Camptothecin results in increased activity of SP3 protein mithramycin A inhibits the reaction [Camptothecin results in increased activity of SP3 protein] |
CTD |
PMID:11261509 |
|
NCBI chr 3:59,644,579...59,689,011
Ensembl chr 3:59,646,015...59,688,692
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases degradation |
ISO |
ATG5 mutant form inhibits the reaction [Camptothecin results in increased degradation of SQSTM1 protein] |
CTD |
PMID:22927544 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
ISO |
Camptothecin results in increased expression of SRXN1 mRNA |
CTD |
PMID:22003191 |
|
NCBI chr 3:147,608,850...147,614,410
Ensembl chr 3:147,609,095...147,632,801
|
|
G |
Stambpl1 |
STAM binding protein-like 1 |
increases methylation |
ISO |
Camptothecin results in increased methylation of STAMBPL1 gene |
CTD |
PMID:30720231 |
|
NCBI chr 1:252,490,125...252,536,113
Ensembl chr 1:252,497,452...252,536,104
|
|
G |
Styxl1 |
serine/threonine/tyrosine interacting-like 1 |
decreases response to substance |
ISO |
STYXL1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr12:23,954,563...23,987,155
Ensembl chr12:23,954,574...23,987,271
|
|
G |
Tab2 |
TGF-beta activated kinase 1/MAP3K7 binding protein 2 |
decreases response to substance |
ISO |
TAB2 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 1:1,999,574...2,017,574
Ensembl chr 1:1,999,596...2,073,896
|
|
G |
Tap1 |
transporter 1, ATP binding cassette subfamily B member |
increases expression |
ISO |
Camptothecin results in increased expression of TAP1 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr20:3,979,302...3,989,669
Ensembl chr20:3,979,035...3,989,669
|
|
G |
Tax1bp3 |
Tax1 binding protein 3 |
increases expression |
ISO |
Camptothecin results in increased expression of TAX1BP3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr10:59,743,356...59,748,063
Ensembl chr10:59,743,544...59,748,062
|
|
G |
Tdp1 |
tyrosyl-DNA phosphodiesterase 1 |
multiple interactions |
ISO |
TDP1 protein inhibits the reaction [Camptothecin results in increased expression of H2AX protein]; TDP1 protein inhibits the reaction [veliparib promotes the reaction [Camptothecin results in increased expression of H2AX protein]] |
CTD |
PMID:21227924 |
|
NCBI chr 6:123,895,860...123,963,688
Ensembl chr 6:123,897,956...123,963,675
|
|
G |
Tert |
telomerase reverse transcriptase |
increases expression multiple interactions |
ISO |
Camptothecin results in increased expression of TERT mRNA 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Camptothecin results in increased phosphorylation of TERT protein]; Acetylcysteine inhibits the reaction [Camptothecin results in increased expression of TERT protein]; Camptothecin results in increased expression of and results in increased phosphorylation of TERT protein; Glutathione inhibits the reaction [Camptothecin results in increased expression of TERT protein]; NFE2L2 protein affects the reaction [Camptothecin results in increased expression of TERT mRNA]; TERT protein affects the reaction [Camptothecin results in increased expression of MYC protein]; TERT protein affects the reaction [Camptothecin results in increased expression of SP1 protein]; Wortmannin inhibits the reaction [Camptothecin results in increased phosphorylation of TERT protein] |
CTD |
PMID:30851366 |
|
NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
|
|
G |
Thbs1 |
thrombospondin 1 |
decreases expression decreases secretion multiple interactions |
ISO |
Camptothecin results in decreased expression of THBS1 mRNA Camptothecin results in decreased secretion of THBS1 protein THBS1 protein inhibits the reaction [Camptothecin results in increased activity of CASP3 protein]; THBS1 protein inhibits the reaction [Camptothecin results in increased cleavage of PARP1 protein] |
CTD |
PMID:16962673 |
|
NCBI chr 3:109,862,120...109,873,466
Ensembl chr 3:109,862,117...109,873,466
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of THRA protein |
CTD |
PMID:25752796 |
|
NCBI chr10:86,657,285...86,684,935
Ensembl chr10:86,657,285...86,684,933
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
Camptothecin binds to and results in decreased activity of THRB protein |
CTD |
PMID:25752796 |
|
NCBI chr15:8,890,578...9,239,815
Ensembl chr15:8,890,578...9,086,282
|
|
G |
Tnfsf9 |
TNF superfamily member 9 |
increases expression |
ISO |
Camptothecin results in increased expression of TNFSF9 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr 9:9,909,942...9,912,276
Ensembl chr 9:9,909,948...9,912,276
|
|
G |
Top1 |
DNA topoisomerase I |
multiple interactions decreases activity decreases response to substance |
ISO EXP |
[Ciprofloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein; [moxifloxacin co-treated with Camptothecin] results in decreased activity of TOP1 protein Camptothecin results in decreased activity of TOP1 protein Camptothecin analog results in decreased activity of TOP1 protein; Camptothecin results in decreased activity of TOP1 protein TOP1 protein mutant form results in decreased susceptibility to Camptothecin |
CTD |
PMID:12097280 PMID:18191106 PMID:20600288 PMID:21056033 PMID:21227924 PMID:23376119 |
|
NCBI chr 3:156,635,688...156,717,686
Ensembl chr 3:156,642,464...156,717,686
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions decreases response to substance increases phosphorylation affects response to substance decreases acetylation increases expression increases response to substance increases activity increases glutathionylation |
ISO EXP |
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole promotes the reaction [Camptothecin results in increased expression of TP53 protein]; [SIRT1 mutant form co-treated with Camptothecin] results in increased acetylation of TP53 protein; Acetylcysteine inhibits the reaction [Camptothecin results in increased expression of TP53 protein modified form]; Camptothecin inhibits the reaction [6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide results in increased acetylation of TP53 protein]; Camptothecin results in increased stability of and results in increased expression of and results in increased phosphorylation of and results in increased activity of TP53 protein; nutlin 3 inhibits the reaction [Camptothecin results in increased expression of TP53 protein]; S-ethyl glutathione inhibits the reaction [Camptothecin results in increased expression of TP53 protein modified form] TP53 mutant form results in decreased susceptibility to Camptothecin; TP53 protein mutant form results in decreased susceptibility to Camptothecin; TP53 protein results in decreased susceptibility to Camptothecin Camptothecin results in increased phosphorylation of TP53 protein TRP53 protein affects the susceptibility to Camptothecin Camptothecin results in decreased acetylation of TP53 protein TP53 protein results in increased susceptibility to Camptothecin Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]; pifithrin inhibits the reaction [Camptothecin promotes the reaction [TP53 protein binds to CREBBP protein]]; pifithrin inhibits the reaction [Camptothecin results in increased activity of TP53 protein] Camptothecin results in increased glutathionylation of TP53 protein |
CTD |
PMID:9673414 PMID:10692111 PMID:11279278 PMID:11741290 PMID:12082016 PMID:13679428 PMID:17555331 PMID:19481069 PMID:20477944 PMID:20978201 PMID:23285096 PMID:24726431 PMID:25269479 PMID:26657896 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tp53i3 |
tumor protein p53 inducible protein 3 |
increases expression |
ISO |
Camptothecin results in increased expression of TP53I3 mRNA |
CTD |
PMID:17374387 |
|
NCBI chr13:75,101,759...75,145,967
Ensembl chr13:75,105,615...75,143,441
|
|
G |
Tp63 |
tumor protein p63 |
decreases expression |
ISO |
Camptothecin results in decreased expression of TP63 protein alternative form |
CTD |
PMID:23376119 |
|
NCBI chr11:78,234,853...78,456,559
Ensembl chr11:78,234,800...78,456,501
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
decreases response to substance |
ISO |
TRAF6 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 3:91,252,829...91,271,607
Ensembl chr 3:91,252,829...91,271,607
|
|
G |
Trim28 |
tripartite motif-containing 28 |
increases expression |
ISO |
Camptothecin results in increased expression of TRIM28 protein modified form |
CTD |
PMID:25977998 |
|
NCBI chr 1:65,544,369...65,551,043
Ensembl chr 1:65,544,373...65,551,043
|
|
G |
Tsg101 |
tumor susceptibility 101 |
decreases response to substance |
ISO |
TSG101 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 1:102,941,151...102,971,017
Ensembl chr 1:102,941,231...102,970,950
|
|
G |
Twf1 |
twinfilin actin-binding protein 1 |
decreases response to substance |
ISO |
TWF1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 7:135,838,647...135,850,542
Ensembl chr 7:135,838,648...135,850,542
|
|
G |
Tyms |
thymidylate synthetase |
increases expression |
ISO |
Camptothecin results in increased expression of TYMS mRNA |
CTD |
PMID:16568373 |
|
NCBI chr 9:121,918,875...121,931,564
Ensembl chr 9:121,918,947...121,931,564
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
decreases methylation |
ISO |
Camptothecin results in decreased methylation of UGT1A6 gene |
CTD |
PMID:30720231 |
|
NCBI chr 9:95,241,609...95,302,822
Ensembl chr 9:95,161,157...95,302,822
|
|
G |
Upf1 |
UPF1, RNA helicase and ATPase |
decreases response to substance |
ISO |
UPF1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr16:20,824,888...20,845,632
Ensembl chr16:20,824,864...20,845,243
|
|
G |
Usp5 |
ubiquitin specific peptidase 5 |
decreases response to substance |
ISO |
USP5 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 4:157,332,735...157,347,803
Ensembl chr 4:157,332,740...157,347,803
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression decreases response to substance |
ISO |
Camptothecin results in decreased expression of VEGFA protein VEGFA protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:16356833 PMID:20116850 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions decreases response to substance |
ISO |
[Butyrates co-treated with Camptothecin] results in decreased expression of XIAP protein; [Camptothecin co-treated with FAS protein] results in decreased expression of XIAP protein Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein] XIAP protein results in decreased susceptibility to Camptothecin |
CTD |
PMID:16061681 PMID:16211302 PMID:19633536 PMID:25449198 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
G |
Xrcc3 |
X-ray repair cross complementing 3 |
decreases expression |
ISO |
Camptothecin results in decreased expression of XRCC3 mRNA |
CTD |
PMID:24792648 |
|
NCBI chr 6:136,366,917...136,380,751
Ensembl chr 6:136,371,555...136,379,348
|
|
G |
Xrcc4 |
X-ray repair cross complementing 4 |
decreases response to substance increases methylation |
ISO |
XRCC4 results in decreased susceptibility to Camptothecin Camptothecin results in increased methylation of XRCC4 gene |
CTD |
PMID:21785230 PMID:30720231 |
|
NCBI chr 2:18,674,496...18,927,463
Ensembl chr 2:18,677,220...18,927,365
|
|
G |
Zap70 |
zeta chain of T cell receptor associated protein kinase 70 |
decreases response to substance |
ISO |
ZAP70 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 9:43,331,149...43,353,097
Ensembl chr 9:43,331,155...43,353,113
|
|
G |
Zc3hc1 |
zinc finger, C3HC-type containing 1 |
decreases response to substance |
ISO |
ZC3HC1 mRNA results in decreased susceptibility to Camptothecin |
CTD |
PMID:25269479 |
|
NCBI chr 4:57,684,678...57,706,613
Ensembl chr 4:57,684,678...57,706,613
|
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
cinchonidine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:47,631,425...47,685,379
Ensembl chr10:47,632,192...47,666,921
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
cinchonidine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:47,587,909...47,631,373
Ensembl chr10:47,588,497...47,630,799
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions decreases expression |
ISO |
cinchonine analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to docetaxel]; cinchonine analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; cinchonine inhibits the reaction [ABCB1 protein results in decreased susceptibility to docetaxel]; cinchonine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel] cinchonine analog results in decreased expression of ABCB1 protein; cinchonine results in decreased expression of ABCB1 protein |
CTD |
PMID:20196146 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
cinchonine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
cinchonine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:47,631,425...47,685,379
Ensembl chr10:47,632,192...47,666,921
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
cinchonine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:47,587,909...47,631,373
Ensembl chr10:47,588,497...47,630,799
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport affects response to substance decreases expression affects transport affects binding multiple interactions |
ISO |
ABCB1 protein results in increased transport of Quinidine ABCB1A protein affects the susceptibility to Quinidine Quinidine results in decreased expression of ABCB1 protein ABCB1 protein affects the transport of Quinidine Quinidine binds to ABCB1 protein methoxyfenozide inhibits the reaction [ABCB1 protein results in increased transport of Quinidine]; Quinidine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Docetaxel]; Quinidine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Paclitaxel]; tebufenozide inhibits the reaction [ABCB1 protein results in increased transport of Quinidine] |
CTD |
PMID:15502009 PMID:15616150 PMID:20196146 PMID:23976943 PMID:26995013 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects response to substance affects activity |
ISO EXP |
ABCB1B protein affects the susceptibility to Quinidine Quinidine affects the activity of ABCB1B protein |
CTD |
PMID:12626638 PMID:15502009 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
decreases expression |
EXP |
Quinidine results in decreased expression of ACADM mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:260,124,418...260,148,589
Ensembl chr 2:260,124,418...260,148,589
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
affects binding multiple interactions |
ISO |
Quinidine binds to ADRA1A protein [Quinidine co-treated with Verapamil] inhibits the reaction [ADRA1A protein results in increased abundance of Inositol 1,4,5-Trisphosphate]; Quinidine inhibits the reaction [ADRA1A protein results in increased abundance of Inositol 1,4,5-Trisphosphate] |
CTD |
PMID:9570190 |
|
NCBI chr15:43,296,997...43,398,314
Ensembl chr15:43,298,794...43,392,451
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
affects binding multiple interactions |
ISO |
Quinidine binds to ADRA1B protein [Quinidine co-treated with Verapamil] inhibits the reaction [ADRA1B protein results in increased abundance of Inositol 1,4,5-Trisphosphate]; Quinidine inhibits the reaction [ADRA1B protein results in increased abundance of Inositol 1,4,5-Trisphosphate] |
CTD |
PMID:9570190 |
|
NCBI chr10:29,392,762...29,450,644
Ensembl chr10:29,392,762...29,450,644
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
affects binding multiple interactions |
ISO |
Quinidine binds to ADRA1D protein [Quinidine co-treated with Verapamil] inhibits the reaction [ADRA1D protein results in increased abundance of Inositol 1,4,5-Trisphosphate]; Quinidine inhibits the reaction [ADRA1D protein results in increased abundance of Inositol 1,4,5-Trisphosphate] |
CTD |
PMID:9570190 |
|
NCBI chr 3:124,129,558...124,145,566
Ensembl chr 3:124,129,558...124,145,566
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
EXP |
Quinidine results in increased expression of ALDOA mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:198,228,387...198,233,988
Ensembl chr 1:198,228,387...198,233,588
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
Quinidine results in increased expression of ASNS mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 4:33,742,876...33,761,106
Ensembl chr 4:33,743,364...33,761,163
|
|
G |
Cat |
catalase |
increases expression |
ISO |
Quinidine results in increased expression of CAT protein |
CTD |
PMID:12708743 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Quinidine results in increased expression of CDKN1A protein |
CTD |
PMID:12243503 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
EXP |
Quinidine results in increased expression of CEACAM1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 1:82,327,955...82,344,345
Ensembl chr 1:82,327,955...82,344,345
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
decreases expression |
EXP |
Quinidine results in decreased expression of CYB5R3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:124,024,003...124,041,564
Ensembl chr 7:124,023,995...124,041,594
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions decreases activity |
ISO |
Quinidine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Quinidine results in decreased activity of CYP1A1 protein |
CTD |
PMID:18420780 PMID:18493746 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
ISO |
Quinidine affects the reaction [CYP1A2 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] Quinidine results in decreased activity of CYP1A2 protein |
CTD |
PMID:15916432 PMID:19053182 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP1B1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP2B10 protein |
CTD |
PMID:18420780 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity multiple interactions |
EXP ISO |
Quinidine results in decreased activity of CYP2C6V1 protein Quinidine affects the reaction [CYP2C19 protein results in increased oxidation of 4-amino-2-phenoxymethanesulfonanilide] |
CTD |
PMID:12814958 PMID:19053182 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP2C29 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp2d2 |
cytochrome P450, family 2, subfamily d, polypeptide 2 |
multiple interactions |
EXP |
Quinidine inhibits the reaction [CYP2D2 protein results in increased metabolism of 3-(2-(N,N-diethyl-N-methylammonium)ethyl)-7-methoxy-4-methylcoumarin] |
CTD |
PMID:19858067 |
|
NCBI chr 7:123,651,827...123,655,896
Ensembl chr 7:123,651,827...123,655,896
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing decreases activity multiple interactions |
ISO EXP |
CYP2D6 protein results in increased metabolism of Quinidine Quinidine results in decreased activity of CYP2D6 protein [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased glutathionylation of Duloxetine Hydrochloride Quinidine results in decreased activity of CYP2D6 gene mutant form; Quinidine results in decreased activity of CYP2D6 protein [Quinidine results in decreased activity of CYP2D6 protein] which affects the susceptibility to Oxycodone; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased chemical synthesis of 16-O-demethylaconitine; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased chemical synthesis of 4-hydroxy-N-desmethyltamoxifen; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased chemical synthesis of Aconitine metabolite; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased hydroxylation of N-desmethyltamoxifen; [Quinidine results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; Quinidine binds to and results in decreased activity of CYP2D6 protein; Quinidine inhibits the reaction [3-(2-(N,N-diethyl-N-methylammonium)ethyl)-7-methoxy-4-methylcoumarin results in increased metabolism of CYP2D6 protein]; Quinidine inhibits the reaction [[CYP2D6 protein results in increased metabolism of 7-methoxy-4-(aminomethyl)coumarin] which results in increased chemical synthesis of Coumarins]; Quinidine inhibits the reaction [CYP2D6 protein affects the metabolism of 1-(3-chlorophenyl)piperazine]; Quinidine inhibits the reaction [CYP2D6 protein results in increased chemical synthesis of Dextrorphan]; Quinidine inhibits the reaction [CYP2D6 protein results in increased hydrolysis of bufuralol]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of auriculasin]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of bufuralol]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of Dextromethorphan]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of tegaserod]; Quinidine inhibits the reaction [CYP2D6 protein results in increased metabolism of YM 758]; Quinidine inhibits the reaction [notopterol results in decreased activity of CYP2D6 protein] |
CTD |
PMID:8819299 PMID:11377097 PMID:11560869 PMID:11673748 PMID:12464242 PMID:12467917 PMID:12569440 PMID:12814958 PMID:14652237 PMID:15155557 PMID:15306208 PMID:15860655 PMID:16035375 PMID:16595712 PMID:17702393 PMID:18238857 PMID:18420780 PMID:19230594 PMID:19328226 PMID:20345925 PMID:20590588 PMID:20669986 PMID:21277363 PMID:21336516 PMID:21915887 PMID:23850985 PMID:24167220 PMID:26599973 PMID:28119166 PMID:28887089 PMID:31515991 PMID:32198085 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity |
ISO |
Quinidine results in decreased activity of CYP2E1 protein |
CTD |
PMID:18420780 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
multiple interactions affects metabolic processing |
ISO |
Quinidine inhibits the reaction [CYP3A4 protein results in increased metabolism of YM 758]; Quinidine inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] CYP3A4 protein affects the metabolism of Quinidine |
CTD |
PMID:2271712 PMID:15784650 PMID:19230594 PMID:19299527 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Depp1 |
DEPP1, autophagy regulator |
increases expression |
ISO |
Quinidine results in increased expression of DEPP1 mRNA |
CTD |
PMID:17567588 |
|
NCBI chr 4:148,780,330...148,784,566
Ensembl chr 4:148,782,479...148,784,562
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
increases expression |
ISO |
Quinidine results in increased expression of FABP1 mRNA |
CTD |
PMID:17567588 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fga |
fibrinogen alpha chain |
increases expression |
EXP |
Quinidine results in increased expression of FGA mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:181,997,562...182,013,726
Ensembl chr 2:182,006,242...182,013,763
|
|
G |
Fgb |
fibrinogen beta chain |
increases expression |
EXP |
Quinidine results in increased expression of FGB mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:182,028,044...182,035,026
Ensembl chr 2:182,027,115...182,038,178
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases activity |
ISO |
Quinidine results in decreased activity of GSTM1 protein |
CTD |
PMID:11807801 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
decreases expression |
EXP |
Quinidine results in decreased expression of GSTM3 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:210,685,338...210,688,133
Ensembl chr 2:210,685,197...210,688,272
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions decreases activity |
ISO |
Quinidine inhibits the reaction [GSTP1 protein affects the metabolism of and results in decreased activity of Ethacrynic Acid] Quinidine results in decreased activity of GSTP1 protein |
CTD |
PMID:11807801 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Hibadh |
3-hydroxyisobutyrate dehydrogenase |
increases expression |
EXP |
Quinidine results in increased expression of HIBADH mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:82,604,369...82,702,429
Ensembl chr 4:82,604,373...82,702,429
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
Quinidine inhibits the reaction [IGF1 protein results in increased activity of KCNH1 protein] |
CTD |
PMID:17520698 |
|
NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
|
|
G |
Inhbe |
inhibin subunit beta E |
increases expression |
ISO |
Quinidine results in increased expression of INHBE mRNA |
CTD |
PMID:15342952 |
|
NCBI chr 7:70,641,423...70,642,848
Ensembl chr 7:70,640,075...70,643,169
|
|
G |
Kcnh1 |
potassium voltage-gated channel subfamily H member 1 |
multiple interactions |
ISO |
Quinidine inhibits the reaction [IGF1 protein results in increased activity of KCNH1 protein] |
CTD |
PMID:17520698 |
|
NCBI chr13:110,920,712...111,232,291
Ensembl chr13:110,920,737...111,232,269
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity affects activity affects binding affects localization affects response to substance decreases response to substance |
ISO |
[Quinidine results in decreased activity of KCNH2 protein] which results in decreased import of Thallium; Acids inhibits the reaction [Quinidine results in decreased activity of KCNH2 protein]; naringenin promotes the reaction [Quinidine results in decreased activity of KCNH2 protein]; Potassium inhibits the reaction [Quinidine results in decreased activity of KCNH2 protein]; Quinidine inhibits the reaction [KCNH2 protein results in increased transport of Thallium]; Quinidine promotes the reaction [naringenin results in decreased activity of KCNH2 protein] Quinidine affects the activity of KCNH2 protein Quinidine binds to KCNH2 protein Quinidine affects the localization of KCNH2 protein mutant form KCNH2 gene SNP affects the susceptibility to Quinidine KCNH2 gene mutant form results in decreased susceptibility to Quinidine |
CTD |
PMID:11741928 PMID:12695533 PMID:15671647 PMID:15673388 PMID:15821840 PMID:16960444 PMID:17042915 PMID:18057881 PMID:18701618 PMID:18724381 PMID:19583963 PMID:21158687 PMID:21362439 PMID:22020101 PMID:24052561 PMID:28551711 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Kcnk1 |
potassium two pore domain channel subfamily K member 1 |
multiple interactions |
ISO |
Quinidine affects the reaction [KCNK1 protein results in increased transport of Potassium]; Quinidine inhibits the reaction [KCNK1 protein results in increased transport of Sodium] |
CTD |
PMID:16847696 |
|
NCBI chr19:58,823,836...58,862,926
Ensembl chr19:58,823,814...58,862,926
|
|
G |
Kcnk18 |
potassium two pore domain channel subfamily K member 18 |
multiple interactions |
ISO |
Quinidine inhibits the reaction [KCNK18 protein results in increased transport of Potassium] |
CTD |
PMID:12754259 |
|
NCBI chr 1:280,383,579...280,397,784
Ensembl chr 1:280,383,579...280,397,784
|
|
G |
Kcnk9 |
potassium two pore domain channel subfamily K member 9 |
multiple interactions |
EXP |
Quinidine inhibits the reaction [KCNK9 protein results in increased transport of Potassium] |
CTD |
PMID:10734076 |
|
NCBI chr 7:113,894,918...113,938,397
Ensembl chr 7:113,903,557...113,937,941
|
|
G |
Lbp |
lipopolysaccharide binding protein |
increases expression |
EXP |
Quinidine results in increased expression of LBP mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 3:154,786,232...154,812,910
Ensembl chr 3:154,786,215...154,813,464
|
|
G |
Lipc |
lipase C, hepatic type |
decreases expression |
EXP |
Quinidine results in decreased expression of LIPC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 8:77,272,582...77,398,485
Ensembl chr 8:77,272,570...77,398,248
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
EXP |
Quinidine results in decreased expression of MYC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
ISO |
Quinidine results in increased expression of NUPR1 mRNA |
CTD |
PMID:17567588 |
|
NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
|
|
G |
Otc |
ornithine transcarbamylase |
decreases expression |
EXP |
Quinidine results in decreased expression of OTC mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:13,524,804...13,601,074
Ensembl chr X:13,524,607...13,601,069
|
|
G |
Pklr |
pyruvate kinase L/R |
decreases expression |
EXP |
Quinidine results in decreased expression of PKLR mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:188,449,158...188,458,034
Ensembl chr 2:188,449,210...188,459,592
|
|
G |
Ptma |
prothymosin alpha |
decreases expression |
EXP |
Quinidine results in decreased expression of PTMA mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 9:93,545,396...93,549,436
Ensembl chr 9:93,545,396...93,549,436
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
EXP |
Quinidine results in increased expression of S100A9 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 2:190,097,436...190,100,209
Ensembl chr 2:190,097,554...190,100,276
|
|
G |
Scn5a |
sodium voltage-gated channel alpha subunit 5 |
affects response to substance |
ISO |
SCN5A gene mutant form affects the susceptibility to Quinidine |
CTD |
PMID:17805561 |
|
NCBI chr 8:128,169,191...128,266,681
Ensembl chr 8:128,169,191...128,266,639
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
EXP ISO |
[Quinidine analog results in decreased activity of SLC22A1 protein] which results in decreased import of Phenylephrine; [Quinidine analog results in decreased activity of SLC22A1 protein] which results in decreased import of Synephrine Quinidine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Quinidine inhibits the reaction [SLC22A1 protein results in increased uptake of Monocrotaline]; Quinidine inhibits the reaction [SLC22A1 protein results in increased uptake of Quercetin]; Quinidine inhibits the reaction [SLC22A1 protein results in increased uptake of retrorsine] |
CTD |
PMID:16141367 PMID:21140131 PMID:23831208 PMID:24799337 PMID:24947867 |
|
NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Quinidine inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Quinidine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:16141367 PMID:21599003 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Quinidine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16141367 |
|
NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
|
|
G |
Slc2a3 |
solute carrier family 2 member 3 |
decreases expression |
ISO |
Quinidine results in decreased expression of SLC2A3 mRNA |
CTD |
PMID:15342952 PMID:17567588 |
|
NCBI chr 4:155,549,991...155,626,018
Ensembl chr 4:155,408,233...155,631,856
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
decreases activity multiple interactions |
ISO |
Quinidine results in decreased activity of SLC47A1 protein Quinidine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:16928787 PMID:22419765 |
|
NCBI chr10:47,631,425...47,685,379
Ensembl chr10:47,632,192...47,666,921
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Quinidine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:47,587,909...47,631,373
Ensembl chr10:47,588,497...47,630,799
|
|
G |
Tagln |
transgelin |
decreases expression |
ISO |
Quinidine results in decreased expression of TAGLN mRNA |
CTD |
PMID:17567588 |
|
NCBI chr 8:50,222,895...50,228,369
Ensembl chr 8:50,222,896...50,231,357
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
EXP |
Quinidine results in increased expression of TIMP1 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr X:1,364,771...1,369,451
Ensembl chr X:1,364,786...1,369,384
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
decreases expression |
EXP |
Quinidine results in decreased expression of TNFRSF1A mRNA |
CTD |
PMID:17522070 |
|
NCBI chr 4:157,864,905...157,877,634
Ensembl chr 4:157,864,969...157,877,633
|
|
G |
Tnfrsf8 |
TNF receptor superfamily member 8 |
decreases expression |
ISO |
Quinidine results in decreased expression of TNFRSF8 protein |
CTD |
PMID:12441127 |
|
NCBI chr 5:163,186,349...163,231,578
Ensembl chr 5:163,186,349...163,231,578
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
EXP |
Quinidine results in decreased expression of TP53 mRNA |
CTD |
PMID:17522070 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects uptake |
ISO |
ABCB1 protein affects the uptake of Quinine analog |
CTD |
PMID:11934808 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects uptake |
EXP |
ABCB1B protein affects the uptake of Quinine analog |
CTD |
PMID:11934808 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Quinine affects the reaction [APP protein binds to APP protein] |
CTD |
PMID:18537544 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity increases expression |
ISO |
Quinine results in increased activity of CYP1A1 protein Quinine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:12451431 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases expression |
ISO |
Quinine results in increased expression of CYP1A2 mRNA |
CTD |
PMID:12451431 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity multiple interactions |
EXP ISO |
Quinine results in decreased activity of CYP2C11 protein Quinine inhibits the reaction [CYP2C9 protein affects the metabolism of Diclofenac] Quinine results in decreased activity of CYP2C9 protein |
CTD |
PMID:11124226 PMID:12814958 PMID:15879494 PMID:16081671 |
|
NCBI chr 1:257,676,172...258,004,428
Ensembl chr 1:257,970,345...258,004,434
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases activity |
EXP ISO |
Quinine results in decreased activity of CYP2C6V1 protein Quinine results in decreased activity of CYP2C19 protein |
CTD |
PMID:11124226 PMID:12814958 PMID:15879494 |
|
NCBI chr 1:147,713,879...147,814,410
Ensembl chr 1:147,713,892...147,888,007
|
|
G |
Cyp2d2 |
cytochrome P450, family 2, subfamily d, polypeptide 2 |
decreases activity multiple interactions |
EXP |
Quinine results in decreased activity of CYP2D2 protein Quinine inhibits the reaction [CYP2D2 protein results in increased metabolism of 3-(2-(N,N-diethyl-N-methylammonium)ethyl)-7-methoxy-4-methylcoumarin] |
CTD |
PMID:12814958 PMID:19858067 |
|
NCBI chr 7:123,651,827...123,655,896
Ensembl chr 7:123,651,827...123,655,896
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
EXP |
Quinine inhibits the reaction [CYP2D6 protein results in increased oxidation of Chlorpyrifos] |
CTD |
PMID:14979094 |
|
NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity affects metabolic processing |
ISO |
Quinine results in decreased activity of CYP3A4 protein CYP3A4 protein affects the metabolism of Quinine |
CTD |
PMID:11124226 PMID:12920490 PMID:15896247 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Grm1 |
glutamate metabotropic receptor 1 |
affects response to substance |
EXP |
GRM1 protein affects the susceptibility to Quinine |
CTD |
PMID:19174448 |
|
NCBI chr 1:4,753,141...5,165,859
Ensembl chr 1:4,753,144...5,165,859
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
decreases activity |
ISO |
Quinine results in decreased activity of GSTM1 protein |
CTD |
PMID:11807801 |
|
NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions decreases activity |
ISO |
Quinine inhibits the reaction [GSTP1 protein affects the metabolism of and results in decreased activity of Ethacrynic Acid] Quinine results in decreased activity of GSTP1 protein |
CTD |
PMID:11807801 |
|
NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Quinine |
CTD |
PMID:19362101 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Quinine |
CTD |
PMID:19362101 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
affects response to substance decreases activity |
ISO |
KCNH2 gene SNP affects the susceptibility to Quinine Quinine results in decreased activity of KCNH2 protein |
CTD |
PMID:12695533 PMID:28551711 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Kcnk18 |
potassium two pore domain channel subfamily K member 18 |
multiple interactions |
ISO |
Quinine inhibits the reaction [KCNK18 protein results in increased transport of Potassium] |
CTD |
PMID:12754259 |
|
NCBI chr 1:280,383,579...280,397,784
Ensembl chr 1:280,383,579...280,397,784
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions increases uptake decreases activity |
EXP ISO |
Quinine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] SLC22A1 protein results in increased uptake of Quinine [Quinine results in decreased activity of SLC22A1] which results in decreased uptake of abacavir; Quinine inhibits the reaction [SLC22A1 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Quinine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Quinine inhibits the reaction [SLC22A1 protein results in increased uptake of Ethidium] Quinine results in decreased activity of SLC22A1; Quinine results in decreased activity of SLC22A1 protein |
CTD |
PMID:16142924 PMID:16263091 PMID:19357179 PMID:25844889 PMID:27504015 PMID:31830554 |
|
NCBI chr 1:48,273,639...48,300,645
Ensembl chr 1:48,273,611...48,300,655
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions decreases activity |
ISO |
Quinine inhibits the reaction [SLC22A2 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Quinine inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Quinine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Quinine inhibits the reaction [SLC22A2 protein results in increased uptake of Ethidium] Quinine results in decreased activity of SLC22A2 protein |
CTD |
PMID:16263091 PMID:19357179 PMID:21599003 PMID:27504015 PMID:31830554 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
Quinine inhibits the reaction [SLC22A3 protein results in increased transport of 1-Methyl-4-phenylpyridinium]; Quinine inhibits the reaction [SLC22A3 protein results in increased uptake of Ethidium] |
CTD |
PMID:16263091 PMID:19357179 |
|
NCBI chr 1:48,433,079...48,521,261
Ensembl chr 1:48,433,079...48,521,256
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
Quinine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:47,631,425...47,685,379
Ensembl chr10:47,632,192...47,666,921
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Quinine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:47,587,909...47,631,373
Ensembl chr10:47,588,497...47,630,799
|
|
G |
Slc9a7 |
solute carrier family 9 member A7 |
decreases activity |
ISO |
Quinine results in decreased activity of SLC9A7 protein |
CTD |
PMID:11279194 |
|
NCBI chr X:2,434,918...2,615,936
Ensembl chr X:2,435,305...2,614,770
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
decreases activity increases uptake multiple interactions |
EXP ISO |
Quinine results in decreased activity of SLCO1A4 protein SLCO1A2 protein results in increased uptake of Quinine naringin inhibits the reaction [SLCO1A2 protein results in increased uptake of Quinine]; Quinine inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate] Quinine inhibits the reaction [SLCO1A4 protein results in increased uptake of Digoxin] |
CTD |
PMID:11883641 PMID:27504015 |
|
NCBI chr 4:175,969,549...176,026,227
Ensembl chr 4:175,969,549...176,026,163
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Quinine Quinine inhibits the reaction [TNF protein results in increased transport of Potassium] |
CTD |
PMID:10783394 PMID:19362101 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
|
G |
Casp3 |
caspase 3 |
increases expression |
EXP |
Strychnine results in increased expression of CASP3 mRNA |
CTD |
PMID:19815060 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
affects binding multiple interactions |
ISO |
Strychnine binds to CHRM2 protein Strychnine promotes the reaction [N-Methylscopolamine binds to CHRM2 protein] |
CTD |
PMID:9495826 PMID:15647330 |
|
NCBI chr 4:64,089,028...64,091,090
Ensembl chr 4:64,088,900...64,091,090
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
affects binding |
EXP ISO |
Strychnine binds to CHRM3 protein |
CTD |
PMID:12435818 PMID:15647330 |
|
NCBI chr17:63,990,599...64,463,222
Ensembl chr17:63,990,599...63,994,169
|
|
G |
Chrm4 |
cholinergic receptor, muscarinic 4 |
multiple interactions |
ISO |
Strychnine promotes the reaction [N-Methylscopolamine binds to CHRM4 protein] |
CTD |
PMID:9495826 |
|
NCBI chr 3:80,833,272...80,841,165
Ensembl chr 3:80,833,272...80,841,006
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
Strychnine results in increased expression of and results in increased degradation of CYP2B1 protein |
CTD |
PMID:7906730 |
|
NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression |
EXP |
Strychnine results in increased expression of CYP2B2 protein |
CTD |
PMID:7906730 |
|
NCBI chr 1:83,103,925...83,119,578
Ensembl chr 1:83,103,925...83,119,193
|
|
G |
Gfap |
glial fibrillary acidic protein |
increases expression |
EXP |
Strychnine results in increased expression of GFAP mRNA |
CTD |
PMID:22954530 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Glra1 |
glycine receptor, alpha 1 |
multiple interactions decreases activity |
ISO EXP |
Strychnine analog binds to and results in decreased activity of GLRA1 protein; Strychnine binds to and results in decreased activity of GLRA1 protein; Strychnine promotes the reaction [Genistein results in decreased activity of GLRA1 protein]; Strychnine promotes the reaction [Quercetin results in decreased activity of GLRA1 protein] Strychnine results in decreased activity of GLRA1 protein Genistein promotes the reaction [Strychnine results in decreased activity of GLRA1 protein]; Quercetin promotes the reaction [Strychnine results in decreased activity of GLRA1 protein] |
CTD |
PMID:7752562 PMID:15081878 PMID:16687139 PMID:20719748 |
|
NCBI chr10:40,851,955...40,954,364
Ensembl chr10:40,855,559...40,953,651
|
|
G |
Glra2 |
glycine receptor, alpha 2 |
decreases activity |
EXP |
Strychnine results in decreased activity of GLRA2 protein |
CTD |
PMID:7752562 |
|
NCBI chr X:30,612,894...30,832,078
Ensembl chr X:30,612,903...30,831,483
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Strychnine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Strychnine results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
|
|
G |
Scn5a |
sodium voltage-gated channel alpha subunit 5 |
multiple interactions |
ISO |
Strychnine binds to and results in decreased activity of SCN5A protein |
CTD |
PMID:21616062 |
|
NCBI chr 8:128,169,191...128,266,681
Ensembl chr 8:128,169,191...128,266,639
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Strychnine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|